Sign in
4

Changes in Ownership

Kiniksa Pharmaceuticals International, plc Filed Acc 0001464583-25-000005

CHIEF ACCOUNTING OFFICER sold 50,490 shares at an average $38.87 ($1,962,781)

  • CHIEF ACCOUNTING OFFICER acquired 39,435 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Megna Michael R · CHIEF ACCOUNTING OFFICER

Table I: Non-derivative

7 lines
Date Transaction Shares Price Value Owned after D/I
2025-10-20 Exercise or conversion : show line 1 in the form 10b5-1 +791 $15.50 $12,261 38,892 D
2025-10-20 Exercise or conversion : show line 2 in the form 10b5-1 +6,195 $12.97 $80,349 45,087 D
2025-10-20 Exercise or conversion : show line 3 in the form 10b5-1 +9,831 $11.10 $109,124 54,918 D
2025-10-20 Exercise or conversion : show line 4 in the form 10b5-1 +9,831 $11.97 $117,677 64,749 D
2025-10-20 Exercise or conversion : show line 5 in the form 10b5-1 +12,787 $10.76 $137,588 77,536 D
2025-10-20 Sale : show line 6 in the form 10b5-1 −37,255 $38.72 $1,442,514 40,281 D
2025-10-20 Sale : show line 7 in the form 10b5-1 −13,235 $39.31 $520,268 27,046 D
Open-market sales · 50,490 sh · avg $38.87 · $1,962,781

Table II: Derivative

5 lines
Date Transaction Shares Owned after D/I
2025-10-20 Exercise or conversion : show line 8 in the form 10b5-1 Share Option −791 0 D
2025-10-20 Exercise or conversion : show line 9 in the form 10b5-1 Share Option −6,195 0 D
2025-10-20 Exercise or conversion : show line 10 in the form 10b5-1 Share Option −9,831 0 D
2025-10-20 Exercise or conversion : show line 11 in the form 10b5-1 Share Option −9,831 0 D
2025-10-20 Exercise or conversion : show line 12 in the form 10b5-1 Share Option −12,787 0 D
Loading xslF345X05/form4-10222025_091045.xml…